Complications of immunotherapy in advanced hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 송영기 | - |
dc.contributor.author | 유정주 | - |
dc.contributor.author | 김상균 | - |
dc.contributor.author | 김영석 | - |
dc.date.accessioned | 2024-06-11T08:00:41Z | - |
dc.date.available | 2024-06-11T08:00:41Z | - |
dc.date.issued | 2024-03 | - |
dc.identifier.issn | 2288-8128 | - |
dc.identifier.issn | 2383-5001 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26109 | - |
dc.description.abstract | Immune checkpoint inhibitors (ICIs) are highly effective in cancer treatment. However, the risks associated with the treatment must be carefully balanced against the therapeutic benefits. Immune-related adverse events (irAEs) are generally unpredictable and may persist over an extended period. In this review, we analyzed common irAEs reported in highly cited original articles and systematic reviews. The prevalent adverse reactions include fatigue, pyrexia, rash, pruritus, diarrhea, decreased appetite, nausea, abdominal pain, constipation, hepatitis, and hypothyroidism. Therefore, it is crucial to conduct evaluations not only of gastrointestinal organs but also of cardiac, neurologic, endocrine (including the frequently affected thyroid), and ophthalmic systems before commencing ICIs. This review further explores commonly reported types of irAEs, specific irAEs associated with each ICI agent, rare yet potentially fatal irAEs, and available treatment options for managing them. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한간암학회 | - |
dc.title | Complications of immunotherapy in advanced hepatocellular carcinoma | - |
dc.title.alternative | Complications of immunotherapy in advanced hepatocellular carcinoma | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.17998/jlc.2023.11.21 | - |
dc.identifier.bibliographicCitation | Journal of Liver Cancer, v.24, no.1, pp 9 - 16 | - |
dc.citation.title | Journal of Liver Cancer | - |
dc.citation.volume | 24 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 9 | - |
dc.citation.endPage | 16 | - |
dc.identifier.kciid | ART003063841 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Immune checkpoint inhibitors | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.subject.keywordAuthor | Carcinoma | - |
dc.subject.keywordAuthor | hepatocellular | - |
dc.subject.keywordAuthor | Side effect | - |
dc.subject.keywordAuthor | drug | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.